Nifoxipam

COPD, severe asthma, sleep apnea, respiratory failure

Nifoxipam enhances GABAergic inhibition, which dose-dependently suppresses brainstem respiratory centers. Patients with chronic obstructive pulmonary disease, severe asthma, sleep apnea, or other conditions compromising baseline respiratory function face elevated risk of respiratory failure. This contraindication is inferred from benzodiazepine class pharmacology — no nifoxipam-specific respiratory data exist.

myasthenia gravis

Benzodiazepines may worsen muscle weakness in patients with myasthenia gravis through enhanced GABAergic inhibition of motor circuits. Nifoxipam's muscle relaxant properties, common to all benzodiazepines, could precipitate myasthenic crisis. No nifoxipam-specific data exist for this condition.

history of paradoxical BZD reactions

Benzodiazepines occasionally produce paradoxical excitation — agitation, aggression, disinhibition, or psychomotor hyperactivity — particularly in certain populations. Patients with a documented history of paradoxical reactions to any benzodiazepine should avoid nifoxipam. No nifoxipam-specific paradoxical reaction data exist.

cirrhosis, severe hepatic insufficiency, acute liver failure

Nifoxipam is metabolized through hepatic phase I and phase II pathways (Meyer 2016, Pettersson Bergstrand 2019). Severe liver disease may substantially impair clearance, prolonging the already extended duration of action (up to 75 hours) and increasing risk of dose accumulation. The compound's unusual UGT profile — requiring enzyme complexes rather than individual UGT1A4 — may make its clearance particularly sensitive to hepatic dysfunction.

pregnancy, breastfeeding

All benzodiazepines are associated with neonatal risks when used during pregnancy, including floppy infant syndrome (neonatal hypotonia, respiratory depression) and neonatal withdrawal. Nifoxipam's extended duration of action may prolong fetal/neonatal exposure. No nifoxipam-specific reproductive toxicity data exist; this contraindication is inferred entirely from benzodiazepine class data.

opioid use, alcohol use, barbiturate use, gabapentinoid use, other benzodiazepine use, Z-drug use

Co-administration of nifoxipam with other CNS depressants dramatically increases the risk of fatal respiratory depression. This combination is the primary mechanism of benzodiazepine-related death. STRIDA case data confirmed that all five nifoxipam intoxication cases involved polysubstance use, and the US NPDS dataset recorded one death across designer benzodiazepine exposures (2014–2017).

acute narrow-angle glaucoma

Some benzodiazepines have been associated with worsening of acute narrow-angle glaucoma. This is a class-level precaution; no nifoxipam-specific ophthalmic data exist.